Published in Angiogenesis on April 11, 2010
Comparing primary tumors and metastatic nodes in head and neck cancer using intravoxel incoherent motion imaging: a preliminary experience. J Comput Assist Tomogr (2013) 0.90
Correlation of a priori DCE-MRI and (1)H-MRS data with molecular markers in neck nodal metastases: Initial analysis. Oral Oncol (2012) 0.90
Rapid ratiometric determination of hemoglobin concentration using UV-VIS diffuse reflectance at isosbestic wavelengths. Opt Express (2010) 0.87
Diffusion-weighted imaging of a prostate cancer xenograft model seen on a 7 Tesla animal MR scanner: comparison of ADC values and pathologic findings. Korean J Radiol (2011) 0.82
Imaging of angiogenesis. Angiogenesis (2010) 0.82
Evaluation of Head and Neck Tumors with Functional MR Imaging. Magn Reson Imaging Clin N Am (2016) 0.79
Texture analysis on parametric maps derived from dynamic contrast-enhanced magnetic resonance imaging in head and neck cancer. World J Radiol (2016) 0.78
Intravoxel incoherent motion diffusion-weighted MRI during chemoradiation therapy to characterize and monitor treatment response in human papillomavirus head and neck squamous cell carcinoma. J Magn Reson Imaging (2016) 0.78
Nodal vascularity as an indicator of cervicofacial metastasis in oral cancer: A Doppler sonographic study. Niger Med J (2014) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev (2003) 11.29
Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst (1992) 8.69
Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol (2007) 6.80
Head and neck cancer. N Engl J Med (1993) 6.33
Molecular imaging. Radiology (2001) 5.67
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol (2005) 3.86
Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res (1999) 3.23
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol (2006) 2.72
Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology (2001) 2.69
Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples. Curr Med Imaging Rev (2009) 2.52
3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res (2003) 2.46
1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology (2006) 2.26
Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol (1999) 2.25
The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol (2006) 2.18
Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys (1996) 2.12
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
Evaluation of the larynx for tumour recurrence by diffusion-weighted MRI after radiotherapy: initial experience in four cases. Br J Radiol (2006) 2.04
Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res (2009) 1.89
Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer (2007) 1.65
Synchronous and metachronous head and neck carcinomas. Cancer (1994) 1.61
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol (2009) 1.52
Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. AJNR Am J Neuroradiol (2007) 1.52
Second primary tumors in patients with oral cancer. Cancer (1992) 1.51
Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys (2007) 1.50
[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2007) 1.45
Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol (2009) 1.40
Usefulness of the apparent diffusion coefficient in line scan diffusion-weighted imaging for distinguishing between squamous cell carcinomas and malignant lymphomas of the head and neck. AJNR Am J Neuroradiol (2005) 1.39
PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med (2006) 1.38
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol (2009) 1.37
In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid singlets at 1.5 T using PRESS excitation with applications to the study of brain and head and neck tumors. J Magn Reson (1998) 1.35
Can pretreatment CT perfusion predict response of advanced squamous cell carcinoma of the upper aerodigestive tract treated with induction chemotherapy? AJNR Am J Neuroradiol (2007) 1.33
Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys (2007) 1.33
Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.32
PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med (2009) 1.31
Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res (1999) 1.28
Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. AJNR Am J Neuroradiol (2006) 1.27
Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol (1999) 1.26
Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. Int J Radiat Oncol Biol Phys (2008) 1.24
Head and neck cancer: an evolving treatment paradigm. Cancer (2008) 1.21
Characterization of pediatric head and neck masses with diffusion-weighted MR imaging. Eur Radiol (2008) 1.19
Computed tomography perfusion of squamous cell carcinoma of the upper aerodigestive tract. Initial results. J Comput Assist Tomogr (2003) 1.18
Non-gaussian analysis of diffusion-weighted MR imaging in head and neck squamous cell carcinoma: A feasibility study. AJNR Am J Neuroradiol (2009) 1.17
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys (2009) 1.16
In vivo 1H MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen tension measurements. AJNR Am J Neuroradiol (2000) 1.15
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol (2009) 1.15
New directions in head and neck imaging. J Surg Oncol (2008) 1.07
Role of diffusion-weighted magnetic resonance imaging in differentiation between the viable and necrotic parts of head and neck tumors. Acta Radiol (2008) 1.05
An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancers. Br J Cancer (1990) 1.02
Head and neck squamous cell carcinoma: CT perfusion can help noninvasively predict intratumoral microvessel density. Radiology (2009) 1.02
Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med (2006) 1.01
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs (2006) 1.01
The role of ultrasound in the detection of cervical lymph node metastases in clinically N0 squamous cell carcinoma of the head and neck. Cancer Imaging (2007) 1.00
Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol (2009) 1.00
Real time non-invasive imaging of receptor-ligand interactions in vivo. J Cell Biochem (2003) 0.99
18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med (2004) 0.97
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int (2005) 0.97
The relationship between enhanced intensity and microvessel density of gastric carcinoma using double contrast-enhanced ultrasonography. Ultrasound Med Biol (2009) 0.95
3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis. J Magn Reson Imaging (2008) 0.95
Imaging angiogenesis. Methods Mol Biol (2009) 0.94
Visualizing head and neck tumors in vivo using near-infrared fluorescent transferrin conjugate. Mol Imaging (2008) 0.94
Prediction of treatment response of head and neck cancers with P-31 MR spectroscopy from pretreatment relative phosphomonoester levels. Acad Radiol (2002) 0.92
Targeting angiogenesis in head and neck cancer. Semin Oncol (2008) 0.92
Diffusion-weighted magnetic resonance imaging to evaluate major salivary gland function before and after radiotherapy. Int J Radiat Oncol Biol Phys (2008) 0.92
Vessel growth and function: depiction with contrast-enhanced MR imaging. Radiology (2009) 0.91
Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin (2008) 0.91
Diagnostic importance of focal defects in the apparent diffusion coefficient-based differentiation between lymphoma and squamous cell carcinoma nodes in the neck. Eur Radiol (2008) 0.88
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. Int J Radiat Oncol Biol Phys (2007) 0.87
Update on molecular diagnostic tests in head and neck cancer. Semin Oncol (2008) 0.84
Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma. PLoS One (2008) 0.82
Dynamic contrast-enhanced brain perfusion imaging: technique and clinical applications. Semin Ultrasound CT MR (2000) 0.82
In vivo lactate signal enhancement using binomial spectral-selective pulses in selective MQ coherence (SS-SelMQC) spectroscopy. Magn Reson Med (2009) 0.82
Proton and phosphorous MR spectroscopy in squamous cell carcinomas of the head and neck. Acad Radiol (2009) 0.82
Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. Int J Cancer (2001) 0.81
Evaluation of tumor proliferation using dynamic contrast enhanced-MRI of oral cavity and oropharyngeal squamous cell carcinoma. Oral Oncol (2003) 0.81
CT perfusion of head and neck tumors: how we do it. AJR Am J Roentgenol (2010) 0.80
Magnetic resonance spectroscopy of head and neck neoplasms. Top Magn Reson Imaging (2004) 0.79
Microvessel density predicts the radiosensitivity of metastatic head and neck squamous cell carcinoma in cervical lymph nodes. Int J Oncol (2001) 0.78
Validation of laser Doppler fluxmetry as a method of assessing neo-angiogenesis in laryngeal tumours. Eur Arch Otorhinolaryngol (2005) 0.76
[Diffusion weighted MRI helps evaluate angiogenesis and vascular endothelial growth factor expression in prostate cancer]. Zhonghua Nan Ke Xue (2009) 0.75
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest (2009) 3.14
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res (2004) 2.36
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One (2007) 2.14
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology (2012) 1.74
The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int (2007) 1.71
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res (2005) 1.67
Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed (2005) 1.65
Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol (2012) 1.64
Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. Radiology (2008) 1.56
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer (2004) 1.55
Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology (2009) 1.55
The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol (2005) 1.52
Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia (2009) 1.52
Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal (2009) 1.39
Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results. Radiology (2003) 1.33
Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys (2007) 1.31
Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology (2005) 1.30
Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data. Magn Reson Med (2008) 1.30
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A (2013) 1.26
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Int J Radiat Oncol Biol Phys (2011) 1.26
Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology (2003) 1.22
Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging. Radiology (2011) 1.17
Semi-automatic deformable registration of prostate MR images to pathological slices. J Magn Reson Imaging (2010) 1.17
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys (2009) 1.16
Multimodality registration without a dedicated multimodality scanner. Mol Imaging (2007) 1.16
Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res (2005) 1.15
MR imaging of the prostate in clinical practice. MAGMA (2008) 1.15
Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology (2009) 1.14
Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases. Int J Radiat Oncol Biol Phys (2011) 1.14
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. Mol Cancer Ther (2006) 1.11
Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations. Radiology (2004) 1.09
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med (2003) 1.09
Murine S factors for liver, spleen, and kidney. J Nucl Med (2003) 1.07
Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology (2007) 1.07
Extension of the intravoxel incoherent motion model to non-gaussian diffusion in head and neck cancer. J Magn Reson Imaging (2012) 1.06
In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res (2007) 1.06
β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest (2013) 1.03
Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors. Clin Cancer Res (2009) 1.02
Functional magnetic resonance imaging in prostate cancer. Eur Urol (2009) 1.01
MRI of the prostate: clinical relevance and emerging applications. J Magn Reson Imaging (2011) 0.99
Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Exp Cell Res (2011) 0.99
The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer. Clin Adv Hematol Oncol (2009) 0.98
Average arterial input function for quantitative dynamic contrast enhanced magnetic resonance imaging of neck nodal metastases. BMC Med Phys (2009) 0.97
Imaging transgene activity in vivo. Cancer Res (2008) 0.97
Accuracy and reproducibility of tumor positioning during prolonged and multi-modality animal imaging studies. Phys Med Biol (2008) 0.93
Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy. BJU Int (2009) 0.93
Mapping Tumor Hypoxia In Vivo Using Pattern Recognition of Dynamic Contrast-enhanced MRI Data. Transl Oncol (2012) 0.92
Prediction of treatment response of head and neck cancers with P-31 MR spectroscopy from pretreatment relative phosphomonoester levels. Acad Radiol (2002) 0.92
Temporal/spatial resolution improvement of in vivo DCE-MRI with compressed sensing-optimized FLASH. Magn Reson Imaging (2012) 0.92
1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization. Cancer Biomark (2008) 0.91
Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyltransferase fused with red fluorescence protein. Acta Oncol (2008) 0.91
Intraobserver variability in the MR determination of tumor volume in squamous cell carcinoma of the pharynx. AJNR Am J Neuroradiol (2004) 0.91
Comparing primary tumors and metastatic nodes in head and neck cancer using intravoxel incoherent motion imaging: a preliminary experience. J Comput Assist Tomogr (2013) 0.90
Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells. Radiother Oncol (2009) 0.90
Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys (2010) 0.90
Correlation of a priori DCE-MRI and (1)H-MRS data with molecular markers in neck nodal metastases: Initial analysis. Oral Oncol (2012) 0.90
In vivo tumor lactate relaxation measurements by selective multiple-quantum-coherence (Sel-MQC) transfer. Magn Reson Med (2004) 0.89
Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data. Magn Reson Imaging (2009) 0.89
Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1H spectroscopic imaging. Clin Cancer Res (2003) 0.87
Diffusion-weighted magnetic resonance imaging of the prostate: improved robustness with stretched exponential modeling. J Comput Assist Tomogr (2012) 0.87
The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR Am J Roentgenol (2012) 0.87
Relationships between LDH-A, lactate, and metastases in 4T1 breast tumors. Clin Cancer Res (2013) 0.86
Fat-free MRI based on magnetization exchange. Magn Reson Med (2010) 0.85
DNA and protein changes caused by disease in human breast tissues probed by the Kubelka-Munk spectral functional. Photochem Photobiol (2002) 0.85
Measurements of tumor tissue oxygen tension using a time-resolved luminescence-based optical oxylite probe: comparison with a paired survival assay. Radiat Res (2002) 0.85
VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin Orthop Relat Res (2004) 0.85
Motion correction of multi-b-value diffusion-weighted imaging in the liver. Acad Radiol (2012) 0.85
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magn Reson Med (2009) 0.85
Diffusion-weighted MRI of the prostate at 3.0 T: comparison of endorectal coil (ERC) MRI and phased-array coil (PAC) MRI-The impact of SNR on ADC measurement. Eur J Radiol (2013) 0.84
Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo. Radiother Oncol (2012) 0.84
Registration of planar bioluminescence to magnetic resonance and x-ray computed tomography images as a platform for the development of bioluminescence tomography reconstruction algorithms. J Biomed Opt (2009) 0.83
Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic resonance imaging. J Urol (2003) 0.83
J-difference lactate editing at 3.0 Tesla in the presence of strong lipids. J Magn Reson Imaging (2008) 0.83
Therapeutic strategy for acute spinal cord contusion injury: cell elimination combined with microsurgical intervention. PLoS One (2007) 0.82
Diagnostic usefulness of water-to-fat ratio and choline concentration in malignant and benign breast lesions and normal breast parenchyma: an in vivo (1) H MRS study. J Magn Reson Imaging (2011) 0.82
Liver regeneration in humans is characterized by significant changes in cellular phosphorus metabolism: assessment using proton-decoupled 31P-magnetic resonance spectroscopic imaging. Magn Reson Med (2005) 0.82
High-field small animal magnetic resonance oncology studies. Phys Med Biol (2013) 0.81
Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI. NMR Biomed (2012) 0.80
In vivo 5-fluorouracil and fluoronucleotide T1 relaxation time measurements using the variable nutation angle method. Magn Reson Med (2004) 0.80
An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: proof of principle. Clin Cancer Res (2005) 0.79
Anatomic segmentation improves prostate cancer detection with artificial neural networks analysis of 1H magnetic resonance spectroscopic imaging. J Magn Reson Imaging (2013) 0.79
Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model. Cancer Biol Ther (2009) 0.78